Product logins

Find logins to all Clarivate products below.


Psoriasis – Access & Reimbursement – Detailed, Expanded Analysis

Related Market Assessment Reports

Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Psoriasis – Current Treatment – Current Treatment: Physician Insights – Psoriasis (EU5)
The psoriasis treatment landscape has significantly evolved in the past few years. A plethora of psoriasis treatments are available in the EU5, ranging from topical agents to conventional systemic…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space…
Report
Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Psoriasis (US)
Psoriasis affects pediatric, adolescent, and adult patients similarly; however, the effective management of pediatric psoriasis is more challenging owing to the limited number of treatments…
Report
Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Psoriasis (US)
The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies in the moderate to severe space, for which conventional systemic and topical…